VITT and Second Doses of Covid-19 Vaccine.
作者信息
Lacy Joanne, Pavord Sue, Brown Kevin E
机构信息
UK Health Security Agency, London, United Kingdom.
Oxford University, Oxford, United Kingdom.
出版信息
N Engl J Med. 2022 Jan 6;386(1):95. doi: 10.1056/NEJMc2118507. Epub 2021 Dec 22.
Abstract
摘要
相似文献
1
VITT and Second Doses of Covid-19 Vaccine.疫苗诱导的免疫性血小板减少症（VITT）与新冠病毒疾病-19疫苗第二剂
N Engl J Med. 2022 Jan 6;386(1):95. doi: 10.1056/NEJMc2118507. Epub 2021 Dec 22.
2
Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia.腺病毒载体新冠疫苗诱导的免疫性血栓性血小板减少症的相关认识。
Blood. 2021 Dec 2;138(22):2256-2268. doi: 10.1182/blood.2021013231.
3
Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein.抗血小板因子 4 抗体导致的 VITT 与 SARS-CoV-2 刺突蛋白不发生交叉反应。
Blood. 2021 Oct 7;138(14):1269-1277. doi: 10.1182/blood.2021012938.
4
Potential Anionic Substances Binding to Platelet Factor 4 in Vaccine-Induced Thrombotic Thrombocytopenia of ChAdOx1-S Vaccine for SARS-CoV-2.用于 SARS-CoV-2 的 ChAdOx1-S 疫苗诱导的血栓性血小板减少性紫癜中与血小板因子 4 结合的潜在阴离子物质。
Front Immunol. 2022 Jan 12;12:782335. doi: 10.3389/fimmu.2021.782335. eCollection 2021.
5
Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways.接种 SARS-CoV-2 疫苗后发生的凝血功能障碍可能源于 SARS-CoV-2 刺突蛋白和腺病毒载体触发的信号通路的综合作用。
Int J Mol Sci. 2021 Oct 6;22(19):10791. doi: 10.3390/ijms221910791.
6
Validation of the newly proposed Brighton Collaboration case definition for vaccine-induced immune thrombocytopenia and thrombosis.验证新提出的用于疫苗诱导的免疫性血小板减少症和血栓形成的布莱顿协作组病例定义。
Vaccine. 2024 Nov 14;42(25):126131. doi: 10.1016/j.vaccine.2024.07.032. Epub 2024 Jul 12.
7
Clinical care pathway for the evaluation of patients with suspected VITT after ChAdOx1 nCoV-19 vaccination.疑似接种 ChAdOx1 nCoV-19 后出现 VITT 患者的临床评估路径。
Blood Adv. 2022 Jun 14;6(11):3315-3320. doi: 10.1182/bloodadvances.2021006862.
8
Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis.新型冠状病毒病疫苗诱导的免疫性血栓性血小板减少症的血栓形成模式和临床结局：系统评价和荟萃分析。
Int J Infect Dis. 2022 Jun;119:130-139. doi: 10.1016/j.ijid.2022.03.034. Epub 2022 Mar 24.
9
No Correlation between Anti-PF4 and Anti-SARS-CoV-2 Antibodies after ChAdOx1 nCoV-19 Vaccination.ChAdOx1 nCoV-19疫苗接种后抗PF4抗体与抗SARS-CoV-2抗体之间无相关性。
N Engl J Med. 2021 Sep 30;385(14):1334-1336. doi: 10.1056/NEJMc2111305. Epub 2021 Aug 25.
10
Potential mechanisms of vaccine-induced thrombosis.疫苗诱导血栓形成的潜在机制。
Eur J Intern Med. 2022 Nov;105:1-7. doi: 10.1016/j.ejim.2022.08.002. Epub 2022 Aug 8.
引用本文的文献
1
Genetic predisposition to vaccine-induced immune thrombotic thrombocytopenia.疫苗诱导的免疫性血栓性血小板减少症的遗传易感性。
Br J Haematol. 2025 Jan;206(1):387-388. doi: 10.1111/bjh.19885. Epub 2024 Nov 10.
2
Subsequent Vaccination against SARS-CoV-2 after Vaccine-Induced Immune Thrombotic Thrombocytopenia.疫苗诱导的免疫性血栓性血小板减少症后再次接种严重急性呼吸综合征冠状病毒2疫苗
J Clin Med. 2024 Sep 14;13(18):5462. doi: 10.3390/jcm13185462.
3
Natural history of anti-PF 4 antibodies in patients with vaccine-induced immune thrombocytopenia and thrombosis.疫苗诱导的免疫性血小板减少症和血栓形成患者中抗PF4抗体的自然史。
Blood Transfus. 2024 May;22(3):246-252. doi: 10.2450/BloodTransfus.544. Epub 2024 Jan 29.
4
Reassurance on bleeding and thrombotic events following second dose BNT162b2 and ChAdOx1 COVID-19 vaccines.关于第二剂BNT162b2和ChAdOx1新冠疫苗后出血和血栓形成事件的情况说明
Lancet Reg Health Eur. 2023 Jul 31;32:100708. doi: 10.1016/j.lanepe.2023.100708. eCollection 2023 Sep.
5
Vaccine-induced immune thrombotic thrombocytopenia: what do we know hitherto?疫苗诱导的免疫性血栓性血小板减少症：我们目前了解多少？
Front Med (Lausanne). 2023 May 16;10:1155727. doi: 10.3389/fmed.2023.1155727. eCollection 2023.
6
Platelet-activating functional assay resolution in vaccine-induced immune thrombotic thrombocytopenia: differential alignment to PF4 ELISA platforms.疫苗诱导的免疫性血栓性血小板减少症中血小板激活功能测定的分辨率：与PF4 ELISA平台的差异比对
Res Pract Thromb Haemost. 2023 Mar 25;7(3):100128. doi: 10.1016/j.rpth.2023.100128. eCollection 2023 Mar.
7
Thrombosis with Thrombocytopenia Syndrome (TTS) After ChAdOx1 nCoV-19 Immunization: An Investigative Case Report.腺病毒载体新冠疫苗（ChAdOx1 nCoV-19）接种后发生伴血小板减少的血栓形成综合征（TTS）：一项调查性病例报告。
Am J Case Rep. 2023 Mar 18;24:e938878. doi: 10.12659/AJCR.938878.
8
Acute limb ischemia secondary to vaccine-induced thrombotic thrombocytopenia.疫苗诱导的血栓性血小板减少症继发急性肢体缺血
Ann Vasc Surg Brief Rep Innov. 2023 Mar;3(1). doi: 10.1016/j.avsurg.2022.100153. Epub 2022 Dec 23.
9
Vaccine-induced immune thrombotic thrombocytopenia.疫苗诱导的免疫性血栓性血小板减少症。
Blood. 2023 Apr 6;141(14):1659-1665. doi: 10.1182/blood.2022017696.
10
COVID-19 Adenoviral Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT), COVID-19-Related Thrombosis, and the Thrombotic Thrombocytopenic Syndromes.新型冠状病毒肺炎腺病毒疫苗诱导的免疫性血栓性血小板减少症（VITT）、新型冠状病毒肺炎相关血栓形成及血栓性血小板减少综合征
Hematol Rep. 2022 Dec 1;14(4):358-372. doi: 10.3390/hematolrep14040050.
本文引用的文献
1
Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine?接种第二剂ChAdOx1 nCov-19疫苗后血栓性血小板减少性紫癜（TTS）的发生率究竟有多高？
Lancet. 2021 Nov 13;398(10313):1801. doi: 10.1016/S0140-6736(21)02285-6.
2
Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis.疫苗诱导的免疫性血小板减少症和血栓形成的临床特征。
N Engl J Med. 2021 Oct 28;385(18):1680-1689. doi: 10.1056/NEJMoa2109908. Epub 2021 Aug 11.
3
Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein.抗血小板因子 4 抗体导致的 VITT 与 SARS-CoV-2 刺突蛋白不发生交叉反应。
Blood. 2021 Oct 7;138(14):1269-1277. doi: 10.1182/blood.2021012938.
4
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination.接种 ChAdOx1 nCoV-19 疫苗后对血小板因子 4 的病理性抗体。
N Engl J Med. 2021 Jun 10;384(23):2202-2211. doi: 10.1056/NEJMoa2105385. Epub 2021 Apr 16.
5
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.接种 ChAdOx1 nCov-19 疫苗后发生血栓性血小板减少症。
N Engl J Med. 2021 Jun 3;384(22):2092-2101. doi: 10.1056/NEJMoa2104840. Epub 2021 Apr 9.
Zotero 插件